Skip to content
Moojaz — موجز
Search
Menu
HomeRegionsMaghrebAfricaMiddle EastEuropeAsiaAmericasWorldSectionsPoliticsEconomySecurityHealthScienceTechnologyAIEnvironmentCultureSportsSearch
← View file

Timeline

Sothema’s planned acquisition of Ramo Pharm

Newest to oldest
Reported information

Sothema–Ramo Pharm: Competition Council publishes takeover notification

In a statement dated 5 November 2026, Morocco’s Competition Council says it has received notification of Sothema’s planned acquisition of all Ramo Pharm’s shares and associated voting rights.

View of Rabat.
Rabat, January 2026. Archive illustration; shows neither the companies nor the Competition Council. CAPTAIN RAJU / Wikimedia Commons, CC0; resized. — CAPTAIN RAJU / Wikimedia Commons — CC0 https://creativecommons.org/publicdomain/zero/1.0/ ; 31 janvier 2026, redimensionnée.

The parties’ summary describes a proposed acquisition of exclusive control in dietary supplement distribution. This follows the acquisition agreement announced in late October, completion of which remained conditional on the Council’s approval among other requirements.

The authority says publication does not prejudge its position on the transaction or establish that the filing is complete. Notification must therefore not be presented as clearance for the purchase or as an already completed takeover.

Sources 3
Reported information

Sothema announces conditional agreement to acquire Ramo Pharm

Sothema announced an agreement on 28 October 2026 to acquire 100% of Ramo Pharm, a Moroccan dietary supplements company. Completion remains subject, among other conditions, to approval from the Competition Council.

Vitamin D2 tablets in an illustrative photograph.
Vitamin D2 supplements photographed in April 2019. Generic illustration, not identified as a Ramo Pharm brand. Mx. Granger, CC0. — Mx. Granger / Wikimedia Commons — CC0 1.0 https://creativecommons.org/publicdomain/zero/1.0/ — compléments de vitamine D2, 20 avril 2019, recadrage existant, sans nouvelle modification.

The group intends to make the transaction the foundation of a wellness and consumer health business alongside general medicine, specialised products and dialysis. It plans to use its distribution networks to develop Ramo Pharm’s brands in Morocco and internationally.

The announcement concerns a signed agreement and does not establish that control has already transferred. According to Le Desk, neither the purchase price nor the completion timetable has been disclosed. Growth and operating synergies remain Sothema’s objectives.

Sources 3